Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Prenetics Group ( (PRE) ) is now available.
On April 2, 2026, Prenetics announced a multi-year global partnership making NBA champion and two-time MVP Giannis Antetokounmpo a global partner of its IM8 brand and a shareholder in the company, marking him as the first NBA athlete to hold equity in a Nasdaq-listed health and longevity firm. The deal aims to tap Antetokounmpo’s 35 million-plus social followers and the NBA’s reach in 215 countries to accelerate IM8’s penetration among 18–34-year-olds and support a 2026 revenue target of $180 million to $200 million.
Management framed the move as deepening IM8’s cross-sport credibility alongside existing equity partners David Beckham, Aryna Sabalenka and F1 driver Ollie Bearman, while underscoring strong alignment with shareholders amid about $160 million in liquidity and no debt. The partnership is intended to bolster IM8’s positioning as a clinically validated, NSF Certified for Sport supplement platform and support Prenetics’ path toward adjusted EBITDA profitability by the fourth quarter of 2027.
The most recent analyst rating on (PRE) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
Spark’s Take on PRE Stock
According to Spark, TipRanks’ AI Analyst, PRE is a Neutral.
The score is driven by strong technical uptrend signals and a bullish earnings-call outlook with robust growth/margin targets and solid liquidity. These positives are tempered by weak underlying financial performance—continued losses and cash burn—and a valuation profile that offers limited support due to negative earnings.
To see Spark’s full report on PRE stock, click here.
More about Prenetics Group
Prenetics Global Limited, listed on Nasdaq under the ticker PRE, is a Hong Kong–based health sciences company focused on consumer health and longevity. Its flagship brand IM8, co-founded with David Beckham, offers premium, science-backed daily nutrition supplements and has rapidly expanded to more than 30 countries, surpassing $100 million in annualized recurring revenue within 11 months of launch.
Average Trading Volume: 262,665
Technical Sentiment Signal: Buy
Current Market Cap: $329.3M
See more insights into PRE stock on TipRanks’ Stock Analysis page.